Blog Cas9 Antibody Cas9 Cell Line Cas9 Dna Sequence Cas9 Enzyme Cas9 Lentivirus Cas9 Mrna Cas9 Nickase
Molybdenum Trioxide purified Antimony Trioxide extrapurified AR Molybdenum Trioxide extrapurified AR Pyridine-Sulfur Trioxide Complex Lead Titanium Trioxide Sulfur Trioxide Pyridine Complex
Acquired genetic mutations can confer resistance to arsenic trioxide (ATO) within the remedy of acute promyelocytic leukemia (APL). Nonetheless, such resistance-conferring mutations are uncommon and don’t clarify most illness recurrence seen within the clinic.
Now we have generated secure ATO-resistant promyelocytic cell strains which are additionally much less delicate to ATRA and the mix of ATO and ATRA in comparison with the delicate cell line.
Characterization of those in-house generated resistant cell strains confirmed important variations in immunophenotype, drug transporter expression, anti-apoptotic protein dependence, and PML-RARA mutation. Gene expression profiling revealed outstanding dysregulation of the mobile metabolic pathways in these ATO resistant APL cell strains.
Glycolytic inhibition by 2-DG was enough and corresponding to the usual of care (ATO) in focusing on the delicate APL cell line. 2-DG was additionally efficient within the in vivo transplantable APL mouse mannequin; nevertheless, it didn’t have an effect on the ATO resistant cell strains. In distinction, the resistant cell strains had been considerably affected by compounds focusing on the mitochondrial respiration when mixed with ATO, regardless of the ATO resistance-conferring genetic mutations or the sample of their anti-apoptotic protein dependency.
Our information exhibit that the addition of mitocans together with ATO can overcome ATO resistance. We additional present that this mixture has the potential within the remedy of non-M3 AML and relapsed APL. The interpretation of this strategy within the clinic must be explored additional.
Colorimetric Comparability of Inside Bleaching with and with out Eradicating Mineral Trioxide Mixture (MTA) on Induced Coronal Tooth Discoloration by MTA
This examine aimed to colorimetric comparability of inner bleaching with and with out eradicating mineral trioxide combination (MTA) on induced coronal tooth discoloration by MTA cement. On this experimental examine, twenty human tooth had been ready.
An OrthoMTA barrier was positioned 1 mm beneath the CEJ. The tooth had been restored with composite resin and had been positioned within the ageing accelerator machine. Then, the specimens had been divided into two teams (n = 10); in group A, a part of the OrthoMTA was eliminated and the glass ionomer was positioned on the OrthoMTA, and in group B, the OrthoMTA remained intact. Inside bleaching was carried out 5 instances in 6-day intervals utilizing 37% carbamide peroxide gel.
Coloration dedication was carried out in 5 phases: baseline, after OrthoMTA discoloration, earlier than OrthoMTA elimination, after OrthoMTA elimination, and after bleaching remedy periods. In group A, eight specimens reached to ∆E < 3.Three after 2 instances inner bleaching remedy, and in group B, 5 specimens reached to ∆E < 3.Three with nearly Three bleaching periods (p > 0.05).
Moreover, 5 specimens reached to the preliminary colour (baseline) after bleaching remedy, Four specimens in group A and 1 specimen in group B. After OrthoMTA elimination, 2 specimens in group A reached to ∆E < 3.3. There was no important distinction between teams with or with out OrthoMTA elimination (p=0.06). Though, the specimens with OrthoMTA elimination required fewer bleaching remedy periods, and the imply worth of ∆E was decrease on this group.
Iridium in Tungsten Trioxide Matrix as an Environment friendly Bi-Purposeful Electrocatalyst for General Water Splitting in Acidic Media
Electrocatalytic water splitting in acidic media is a promising technique for grid scale manufacturing of hydrogen utilizing renewable power, however challenges nonetheless exist within the growth of superior catalysts with each excessive exercise and stability.
Herein, it’s reported that iridium doped tungsten trioxide (Ir-doped WO3 ) with arrayed construction and confined Ir websites is an environment friendly and sturdy bi-functional catalyst for general acidic water splitting. A low overpotential (258 mV) is required to realize an oxygen evolution response present density of 10 mA cm-2 in 0.5 m H2 SO4 answer.
In the meantime, Ir-doped WO3 processes the same intrinsic exercise to Pt/C towards hydrogen evolution response. General water splitting utilizing the bi-functional Ir-doped WO3 catalyst exhibits low cell voltages of 1.56 and 1.68 V to drive the present densities of 10 and 100 mA cm-2 , respectively, with solely 16 mV decay noticed after 60 h steady electrolysis underneath the present density of 100 mA cm-2 . Structural evaluation and density useful idea calculation point out that the adjusted coordination setting of Ir inside the crystalline matrix of WO3 contributes to the excessive exercise and sturdiness.
Pulpal response to mineral trioxide combination containing phosphorylated pullulan-based capping materials
This examine aimed to judge the pulpal responses of monkey’s pulp after direct pulp capping (DPC) with the novel mineral trioxide combination containing phosphorylated pullulan-based materials (MTAPPL). Seventy-two tooth had been randomly divided into 4 teams: MTAPPL; Nex-Cem MTA (NX);
TheraCal LC (TH); and Dycal (DY). Histopathological adjustments within the pulps had been noticed at days 3, 7 and 70. On day 3, delicate inflammatory responses had been noticed within the MTAPPL, no to reasonable inflammatory responses within the TH, whereas reasonable inflammatory responses within the NX and DY. No mineralized tissue formation (MTF) was noticed in all teams.
On day 7, no or delicate inflammatory responses had been noticed in all teams. Preliminary MTF was noticed aside from DY. No irritation with full MTF together with presence of odontoblast-like cells was noticed within the MTAPPL, NX and TH teams at day 70. These findings point out that MTAPPL might be an environment friendly DPC materials.
Liquiritigenin protects towards arsenic trioxide-induced liver damage by inhibiting oxidative stress and enhancing mTOR-mediated autophagy
Liquiritigenin (LQ) has protecting results towards varied hepatotoxicities. Nonetheless, its particular position on arsenic trioxide (ATO)-induced hepatotoxicity and the associated biomolecular mechanisms stay unclear.
The aim of this examine is to discover the protecting actions of LQ on ATO-induced hepatotoxicity and its biomolecular mechanisms in mice. LQ was administered orally at 20 and 40 mg/kg per day for seven consecutive days with an intraperitoneal injection of ATO (5 mg/kg). Liver damage was induced by ATO and was alleviated by remedy with LQ as mirrored by diminished histopathological injury of liver and decreased serum ALT, AST, and ALP ranges.
The era of intracellular ROS induced by ATO was attenuated after LQ remedy. The degrees of SOD, CAT, and GSH had been elevated with LQ administration whereas MDA ranges decreased. LQ mitigated elevated TNF-α and IL-6 ranges in addition to the hepatic mitochondrial injury brought on by ATO. Furthermore, LQ upregulated the expression of LC3-II and enhanced autophagy within the liver of ATO-induced mice. Additional research indicated that LQ considerably suppressed the expression of p-PI3K, p-AKT, and p-mTOR in ATO-induced mice.
 Antibody) Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| 20-abx304514 | Abbexa |
|
|
 Antibody) Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| 20-abx131326 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| 20-abx131327 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| 20-abx135733 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| 20-abx113871 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| abx036894-100ug | Abbexa | 100 ug | EUR 391 |
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| abx037731-100ug | Abbexa | 100 ug | EUR 391 |
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| 20-abx005887 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| abx025653-400ul | Abbexa | 400 ul | EUR 523 |
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| abx025653-80l | Abbexa | 80 µl | EUR 286 |
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| abx028710-400ul | Abbexa | 400 ul | EUR 523 |
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| abx028710-80l | Abbexa | 80 µl | EUR 286 |
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| 20-abx321401 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| 20-abx321402 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| 20-abx321947 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody |
|||
| 20-abx322547 | Abbexa |
|
|
Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody |
|||
| abx235264-100ug | Abbexa | 100 ug | EUR 481 |
 Mouse Molybdenum cofactor sulfurase, Mocos ELISA KIT |
|||
| ELI-16543m | Lifescience Market | 96 Tests | EUR 865 |
 Bovine Molybdenum cofactor sulfurase, MOCOS ELISA KIT |
|||
| ELI-19415b | Lifescience Market | 96 Tests | EUR 928 |
 Human Molybdenum cofactor sulfurase, MOCOS ELISA KIT |
|||
| ELI-20833h | Lifescience Market | 96 Tests | EUR 824 |
 Antibody (HRP)) Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody (HRP) |
|||
| 20-abx304515 | Abbexa |
|
|
 Antibody (FITC)) Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody (FITC) |
|||
| 20-abx304516 | Abbexa |
|
|
 Antibody (Biotin)) Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody (Biotin) |
|||
| 20-abx304517 | Abbexa |
|
|
 ELISA Kit) Cow Molybdenum cofactor sulfurase (MOCOS) ELISA Kit |
|||
| abx516487-96tests | Abbexa | 96 tests | EUR 911 |
 ELISA Kit) Mouse Molybdenum cofactor sulfurase (MOCOS) ELISA Kit |
|||
| abx516489-96tests | Abbexa | 96 tests | EUR 739 |
 Bovine MOCOS/ Molybdenum cofactor sulfurase ELISA Kit |
|||
| E0183Bo | Sunlong | 1 Kit | EUR 717 |
 Mouse Mocos/ Molybdenum cofactor sulfurase ELISA Kit |
|||
| E0967Mo | Sunlong | 1 Kit | EUR 632 |
 Human MOCOS/ Molybdenum cofactor sulfurase ELISA Kit |
|||
| E1626Hu | Sunlong | 1 Kit | EUR 605 |
 ELISA Kit) Human Molybdenum cofactor sulfurase (MOCOS) ELISA Kit |
|||
| abx250798-96tests | Abbexa | 96 tests | EUR 668 |
 Protein) Human Molybdenum Cofactor Synthesis 1 (MOCS1) Protein |
|||
| 20-abx650079 | Abbexa |
|
|
 Protein) Mouse Molybdenum Cofactor Synthesis 1 (MOCS1) Protein |
|||
| 20-abx650080 | Abbexa |
|
|
 ELISA kit for Human Molybdenum cofactor sulfurase |
|||
| EK3232 | SAB | 96 tests | EUR 553 |
|
Description: Enzyme-linked immunosorbent assay kit for quantification of Human Molybdenum cofactor sulfurase in samples from serum, plasma, tissue homogenates and other biological fluids. |
|||
 ELISA Kit) Human MOCOS(Molybdenum cofactor sulfurase) ELISA Kit |
|||
| EH1514 | FN Test | 96T | EUR 567.6 |
|
Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Homo sapiens;Sensitivity: 0.188 ng/ml |
|||
 Polyclonal Antibody (Human)) Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Human) |
|||
| 4-PAC623Hu01 | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Human Molybdenum Cofactor Synthesis 1 (MOCS1) |
|||
 Polyclonal Antibody (Mouse)) Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Mouse) |
|||
| 4-PAC623Mu01 | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Mouse Molybdenum Cofactor Synthesis 1 (MOCS1) |
|||
 MOCS2 Molybdenum Cofactor Synthesis 2 Human Recombinant Protein |
|||
| PROTO96033-1 | BosterBio | Regular: 10ug | EUR 317 |
|
Description: MOCS2 Human Recombinant produced in E. coli is a single polypeptide chain containing 224 amino acids (1-188) and having a molecular mass of 25.0 kDa.;MOCS2 is fused to a 36 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques. |
|||
 ELISA Kit) Human Molybdenum Cofactor Synthesis 2 (MOCS2) ELISA Kit |
|||
| abx381488-96tests | Abbexa | 96 tests | EUR 911 |
 Purified GFP |
|||
| AG45-0205-Z | Immunology Consultants Laboratory | 0.1 mg | EUR 228 |
 Ovalbumin, purified |
|||
| O705084 | Bio Basic | 1g | EUR 67.4 |
 Mocos ELISA Kit| Mouse Molybdenum cofactor sulfurase ELISA Kit |
|||
| EF015558 | Lifescience Market | 96 Tests | EUR 689 |
 MOCOS ELISA Kit| Bovine Molybdenum cofactor sulfurase ELISA Kit |
|||
| EF011614 | Lifescience Market | 96 Tests | EUR 689 |
 Polyclonal Antibody (Human), Biotinylated) Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Human), Biotinylated |
|||
| 4-PAC623Hu01-Biotin | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Human Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with Biotin. |
|||
 Polyclonal Antibody (Human), Cy3) Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Human), Cy3 |
|||
| 4-PAC623Hu01-Cy3 | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Human Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with Cy3. |
|||
 Polyclonal Antibody (Human), PE) Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Human), PE |
|||
| 4-PAC623Hu01-PE | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Human Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with PE. |
|||
 Polyclonal Antibody (Mouse), APC) Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Mouse), APC |
|||
| 4-PAC623Mu01-APC | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Mouse Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with APC. |
|||
 Polyclonal Antibody (Mouse), Biotinylated) Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Mouse), Biotinylated |
|||
| 4-PAC623Mu01-Biotin | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Mouse Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with Biotin. |
|||
 Polyclonal Antibody (Mouse), FITC) Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Mouse), FITC |
|||
| 4-PAC623Mu01-FITC | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Mouse Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with FITC. |
|||
 Polyclonal Antibody (Mouse), HRP) Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Mouse), HRP |
|||
| 4-PAC623Mu01-HRP | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Mouse Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with HRP. |
|||
 Polyclonal Antibody (Human), APC) Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Human), APC |
|||
| 4-PAC623Hu01-APC | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Human Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with APC. |
|||
 Polyclonal Antibody (Human), FITC) Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Human), FITC |
|||
| 4-PAC623Hu01-FITC | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Human Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with FITC. |
|||
 Polyclonal Antibody (Human), HRP) Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Human), HRP |
|||
| 4-PAC623Hu01-HRP | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Human Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with HRP. |
|||
 Polyclonal Antibody (Mouse), Cy3) Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Mouse), Cy3 |
|||
| 4-PAC623Mu01-Cy3 | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Mouse Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with Cy3. |
|||
 Polyclonal Antibody (Mouse), PE) Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Mouse), PE |
|||
| 4-PAC623Mu01-PE | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Mouse Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with PE. |
|||
 Polyclonal Antibody (Human), APC-Cy7) Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Human), APC-Cy7 |
|||
| 4-PAC623Hu01-APC-Cy7 | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Human Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with APC-Cy7. |
|||
 Polyclonal Antibody (Mouse), APC-Cy7) Molybdenum Cofactor Synthesis 1 (MOCS1) Polyclonal Antibody (Mouse), APC-Cy7 |
|||
| 4-PAC623Mu01-APC-Cy7 | Cloud-Clone |
|
|
|
Description: A Rabbit polyclonal antibody against Mouse Molybdenum Cofactor Synthesis 1 (MOCS1). This antibody is labeled with APC-Cy7. |
|||
 Purified Water, 50ML |
|||
| X137-50ML | Arbor Assays | 50ML | EUR 122 |
 Purified, Human HEMOGLOBIN |
|||
| DAG109 | Creative Diagnostics | 20mg | EUR 907 |
 AFP Antigen (Purified） |
|||
| E62C00201 | EnoGene | 20ug | EUR 382 |
) CEA Antigen (Purified) |
|||
| E62C01001 | EnoGene | 20ug | EUR 382 |
) Myoglobin antigen (Purified) |
|||
| E64C00401 | EnoGene | 100ug | EUR 375 |
Myoglobin antigen (Purified) |
|||
| E64C00401a | EnoGene | 20ug | EUR 343 |
 Anti-Cytokeratins Purified |
|||
| 11-108-C025 | ExBio | 0.025 mg | EUR 99 |
Anti-Cytokeratins Purified |
|||
| 11-108-C100 | ExBio | 0.1 mg | EUR 158 |
 Anti-MFG Purified |
|||
| 11-113-C025 | ExBio | 0.025 mg | EUR 90 |
Anti-MFG Purified |
|||
| 11-113-C100 | ExBio | 0.1 mg | EUR 140 |
 Anti-p53 Purified |
|||
| 11-114-C025 | ExBio | 0.025 mg | EUR 104 |
Anti-p53 Purified |
|||
| 11-114-C100 | ExBio | 0.1 mg | EUR 167 |
 Anti-CDK1 Purified |
|||
| 11-115-C025 | ExBio | 0.025 mg | EUR 108 |
Anti-CDK1 Purified |
|||
| 11-115-C100 | ExBio | 0.1 mg | EUR 177 |
 Anti-hTSH Purified |
|||
| 11-124-C025 | ExBio | 0.025 mg | EUR 90 |
Anti-hTSH Purified |
|||
| 11-124-C100 | ExBio | 0.1 mg | EUR 140 |
Anti-hTSH Purified |
|||
| 11-125-C025 | ExBio | 0.025 mg | EUR 90 |
Anti-hTSH Purified |
|||
| 11-125-C100 | ExBio | 0.1 mg | EUR 140 |
 Anti-hGH Purified |
|||
| 11-126-C025 | ExBio | 0.025 mg | EUR 99 |
Anti-hGH Purified |
|||
| 11-126-C100 | ExBio | 0.1 mg | EUR 158 |
 Anti-Lactoferrin Purified |
|||
| 11-128-C025 | ExBio | 0.025 mg | EUR 99 |
Anti-Lactoferrin Purified |
|||
| 11-128-C100 | ExBio | 0.1 mg | EUR 158 |
 Anti-Ikaros Purified |
|||
| 11-159-C025 | ExBio | 0.025 mg | EUR 99 |
Anti-Ikaros Purified |
|||
| 11-159-C100 | ExBio | 0.1 mg | EUR 158 |
 Anti-PCNA Purified |
|||
| 11-182-C025 | ExBio | 0.025 mg | EUR 99 |
Anti-PCNA Purified |
|||
| 11-182-C100 | ExBio | 0.1 mg | EUR 158 |
 Anti-NG2 Purified |
|||
| 11-199-C025 | ExBio | 0.025 mg | EUR 99 |
Anti-NG2 Purified |
|||
| 11-199-C100 | ExBio | 0.1 mg | EUR 158 |
 Anti-Insulin Purified |
|||
| 11-246-C025 | ExBio | 0.025 mg | EUR 99 |
Anti-Insulin Purified |
|||
| 11-246-C100 | ExBio | 0.1 mg | EUR 158 |
 Anti-MAP2 Purified |
|||
| 11-253-C025 | ExBio | 0.025 mg | EUR 113 |
Anti-MAP2 Purified |
|||
| 11-253-C100 | ExBio | 0.1 mg | EUR 186 |
 Anti-Vimentin Purified |
|||
| 11-254-C025 | ExBio | 0.025 mg | EUR 113 |
Anti-Vimentin Purified |
|||
| 11-254-C100 | ExBio | 0.1 mg | EUR 186 |
 Anti-GFAP Purified |
|||
| 11-255-C025 | ExBio | 0.025 mg | EUR 113 |
Anti-GFAP Purified |
|||
| 11-255-C100 | ExBio | 0.1 mg | EUR 186 |
 Anti-Transferrin Purified |
|||
| 11-258-C025 | ExBio | 0.025 mg | EUR 99 |
Anti-Transferrin Purified |
|||
| 11-258-C100 | ExBio | 0.1 mg | EUR 158 |
 Anti-HRP Purified |
|||
| 11-262-C025 | ExBio | 0.025 mg | EUR 90 |
Anti-HRP Purified |
|||
| 11-262-C100 | ExBio | 0.1 mg | EUR 140 |
 Anti-Phosphotyrosine Purified |
|||
| 11-263-C025 | ExBio | 0.025 mg | EUR 113 |
Anti-Phosphotyrosine Purified |
|||
| 11-263-C100 | ExBio | 0.1 mg | EUR 186 |
 Anti-LCK Purified |
|||
| 11-269-C025 | ExBio | 0.025 mg | EUR 113 |
Anti-LCK Purified |
|||
| 11-269-C100 | ExBio | 0.1 mg | EUR 186 |
 Anti-BrdU Purified |
|||
| 11-286-C025 | ExBio | 0.025 mg | EUR 108 |
Anti-BrdU Purified |
|||
| 11-286-C100 | ExBio | 0.1 mg | EUR 177 |
 Anti-PSA Purified |
|||
| 11-289-C025 | ExBio | 0.025 mg | EUR 90 |
Anti-PSA Purified |
|||
| 11-289-C100 | ExBio | 0.1 mg | EUR 140 |
 Anti-VCP Purified |
|||
| 11-300-C025 | ExBio | 0.025 mg | EUR 117 |
Anti-VCP Purified |
|||
| 11-300-C100 | ExBio | 0.1 mg | EUR 195 |
 Anti-GAPDHS Purified |
|||
| 11-301-C025 | ExBio | 0.025 mg | EUR 113 |
Anti-GAPDHS Purified |
|||
| 11-301-C100 | ExBio | 0.1 mg | EUR 186 |
 Anti-p21Waf1 Purified |
|||
| 11-338-C025 | ExBio | 0.025 mg | EUR 108 |
Anti-p21Waf1 Purified |
|||
| 11-338-C100 | ExBio | 0.1 mg | EUR 177 |
 Anti-TRIM Purified |
|||
| 11-344-C025 | ExBio | 0.025 mg | EUR 113 |
Anti-TRIM Purified |
|||
| 11-344-C100 | ExBio | 0.1 mg | EUR 186 |
 Anti-SIT Purified |
|||
| 11-345-C025 | ExBio | 0.025 mg | EUR 113 |
Anti-SIT Purified |
|||
| 11-345-C100 | ExBio | 0.1 mg | EUR 186 |
 Anti-PAG1 Purified |
|||
| 11-346-C025 | ExBio | 0.025 mg | EUR 122 |
Anti-PAG1 Purified |
|||
| 11-346-C100 | ExBio | 0.1 mg | EUR 204 |
Anti-PAG1 Purified |
|||
| 11-347-C025 | ExBio | 0.025 mg | EUR 122 |
Anti-PAG1 Purified |
|||
| 11-347-C100 | ExBio | 0.1 mg | EUR 204 |
 Anti-NHERF1 Purified |
|||
| 11-348-C025 | ExBio | 0.025 mg | EUR 122 |
Anti-NHERF1 Purified |
|||
| 11-348-C100 | ExBio | 0.1 mg | EUR 204 |
 Anti-DAXX Purified |
|||
| 11-351-C025 | ExBio | 0.025 mg | EUR 108 |
Anti-DAXX Purified |
|||
| 11-351-C100 | ExBio | 0.1 mg | EUR 177 |
 Anti-LAT Purified |
|||
| 11-360-C025 | ExBio | 0.025 mg | EUR 113 |
Anti-LAT Purified |
|||
| 11-360-C100 | ExBio | 0.1 mg | EUR 186 |
Anti-Vimentin Purified |
|||
| 11-369-C025 | ExBio | 0.025 mg | EUR 113 |
Anti-Vimentin Purified |
|||
| 11-369-C100 | ExBio | 0.1 mg | EUR 186 |
 Anti-Tenascin Purified |
|||
| 11-370-C025 | ExBio | 0.025 mg | EUR 108 |
Anti-Tenascin Purified |
|||
| 11-370-C100 | ExBio | 0.1 mg | EUR 177 |
 Anti-STAT1 Purified |
|||
| 11-371-C025 | ExBio | 0.025 mg | EUR 122 |
Anti-STAT1 Purified |
|||
| 11-371-C100 | ExBio | 0.1 mg | EUR 204 |
 Anti-NTAL Purified |
|||
| 11-373-C025 | ExBio | 0.025 mg | EUR 122 |
Anti-NTAL Purified |
|||
| 11-373-C100 | ExBio | 0.1 mg | EUR 204 |
Anti-NTAL Purified |
|||
| 11-374-C025 | ExBio | 0.025 mg | EUR 122 |
Anti-NTAL Purified |
|||
| 11-374-C100 | ExBio | 0.1 mg | EUR 204 |
 Anti-FYN Purified |
|||
| 11-375-C025 | ExBio | 0.025 mg | EUR 122 |
Anti-FYN Purified |
|||
| 11-375-C100 | ExBio | 0.1 mg | EUR 204 |
 Anti-SYK Purified |
|||
| 11-376-C025 | ExBio | 0.025 mg | EUR 122 |
Anti-SYK Purified |
|||
| 11-376-C100 | ExBio | 0.1 mg | EUR 204 |
 Anti-LYN Purified |
|||
| 11-377-C025 | ExBio | 0.025 mg | EUR 122 |
Anti-LYN Purified |
|||
| 11-377-C100 | ExBio | 0.1 mg | EUR 204 |
 Anti-CSK Purified |
|||
| 11-378-R025 | ExBio | 0.025 ml | EUR 122 |
Anti-CSK Purified |
|||
| 11-378-R100 | ExBio | 0.1 ml | EUR 204 |
 Anti-LIME1 Purified |
|||
| 11-400-C025 | ExBio | 0.025 mg | EUR 122 |
Anti-LIME1 Purified |
|||
| 11-400-C100 | ExBio | 0.1 mg | EUR 204 |
Anti-LIME1 Purified |
|||
| 11-401-C025 | ExBio | 0.025 mg | EUR 122 |
Anti-LIME1 Purified |
|||
| 11-401-C100 | ExBio | 0.1 mg | EUR 204 |
 Anti-SLP76 Purified |
|||
| 11-402-C025 | ExBio | 0.025 mg | EUR 122 |
Anti-SLP76 Purified |
|||
| 11-402-C100 | ExBio | 0.1 mg | EUR 204 |
Anti-STAT1 Purified |
|||
| 11-405-C025 | ExBio | 0.025 mg | EUR 122 |
Anti-STAT1 Purified |
|||
| 11-405-C100 | ExBio | 0.1 mg | EUR 204 |
 Anti-SOCS3 Purified |
|||
| 11-406-C025 | ExBio | 0.025 mg | EUR 122 |
Anti-SOCS3 Purified |
|||
| 11-406-C100 | ExBio | 0.1 mg | EUR 204 |
Anti-PAG1 Purified |
|||
| 11-409-C025 | ExBio | 0.025 mg | EUR 122 |
Anti-PAG1 Purified |
|||
| 11-409-C100 | ExBio | 0.1 mg | EUR 204 |
Anti-LIME1 Purified |
|||
| 11-410-C025 | ExBio | 0.025 mg | EUR 122 |
Anti-LIME1 Purified |
|||
| 11-410-C100 | ExBio | 0.1 mg | EUR 204 |
Anti-SLP76 Purified |
|||
| 11-412-C025 | ExBio | 0.025 mg | EUR 122 |
In conclusion, our findings present that LQ protects towards ATO-induced hepatotoxicity as a consequence of its antioxidant and anti inflammatory actions and enhancement of autophagy mediated by the PI3K/AKT/mTOR signaling pathway in mice.
